rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PCSA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Processa Pharmaceuticals issues stockholder letter, files 8-K with SEC
      Nov 5Investing.comPCSA
      Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

      VERO BEACH, FL, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases, today announced its participation in two upcoming conferences. Sheila Gujrathi, M.D., Executive Chair of Processa’s Board of Directors, will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, November 16, at 4 p

      Nov 5Yahoo FinancePCSA
      Processa Pharmaceuticals Announces Key Leadership Appointments

      VERO BEACH, FL, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory diseases, today announced key leadership appointments to support the Company’s next phase of growth: Gregory J. Flesher, Chief Operating OfficerCraig Coburn, Ph.D., Executive Vice President, Head of ResearchAshley Hall, J.D., Executive Vice President,

      Nov 4Yahoo FinancePCSA
      Processa gets FDA clearance for Phase 2 urticaria study
      Oct 29Investing.comPCSA
      Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208
      Sep 11Investing.comPCSA
      Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push
      Sep 10Investing.comPCSAWFC
      Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

      VERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced its participation in two upcoming investor conferences. Sheila Gujrathi, M.D., a member of the Processa board of directors and founder and former executive chair of Vidya Therapeutics, will give a company presentation at the following: Thursday,

      Sep 1Yahoo FinancePCSA

      This is the newest page. Registered accounts read further back.